Belbuca and Suboxone are not the same medication. They share a common active ingredient, buprenorphine, but they are FDA-approved for completely different medical conditions, contain different formulations, and are dosed at very different levels. Belbuca treats chronic pain, while Suboxone treats opioid addiction. They are not interchangeable.
The Same Core Drug, Two Different Purposes
Buprenorphine is the active ingredient in both Belbuca and Suboxone. It’s a partial opioid, meaning it activates opioid receptors in the brain but only to a limited degree. Unlike full opioids such as morphine or fentanyl, buprenorphine has a built-in ceiling effect: past a certain dose, its effects plateau rather than continuing to increase. This ceiling also applies to respiratory depression, the cause of most opioid overdose deaths, which makes buprenorphine safer than many alternatives.
That shared ingredient is where the similarities largely end. The FDA approved Belbuca in 2015 specifically for the management of chronic pain. Suboxone, on the other hand, is approved to treat opioid addiction and is meant to be used alongside behavioral therapy or counseling. Prescribing one for the other’s intended purpose would be off-label use.
Different Ingredients
Belbuca contains only buprenorphine. Suboxone contains buprenorphine combined with naloxone, a drug that blocks opioid receptors. Naloxone was added to Suboxone as a deterrent against misuse. When Suboxone is taken as directed (dissolved in the mouth), the naloxone is poorly absorbed and has little effect. But if someone were to inject it, the naloxone would activate fully and trigger immediate withdrawal symptoms.
This combination design is specific to addiction treatment formulations. Pain management formulations like Belbuca don’t include naloxone because the misuse deterrent isn’t part of their clinical purpose.
Dosing Is Drastically Different
One of the biggest practical differences is the dose. Belbuca is dosed in micrograms, typically ranging from 75 to 900 micrograms. Suboxone is dosed in milligrams, commonly between 2 and 24 milligrams of buprenorphine per day. That means a standard Suboxone dose can contain many times more buprenorphine than a Belbuca dose.
This gap exists because the two medications are doing fundamentally different jobs. For pain relief, smaller amounts of buprenorphine activate enough opioid receptors to reduce pain signals. For addiction treatment, much higher doses are needed to occupy opioid receptors thoroughly enough to reduce cravings and block the effects of other opioids a person might take.
How Each One Is Taken
Both medications are thin films that dissolve in the mouth, but they’re placed in slightly different locations. Belbuca is a buccal film, meaning it’s applied to the inside of the cheek. Suboxone is a sublingual film, placed under the tongue. In both cases, the buprenorphine absorbs through the lining of the mouth directly into the bloodstream.
Because both dissolve in the mouth, they share a notable side effect. The FDA issued a warning that buprenorphine medicines dissolved in the mouth are associated with serious dental problems, including tooth decay, cavities, oral infections, and tooth loss. A review of 305 reported cases found these issues even in patients with no prior dental problems. The median time to diagnosis was about two years of use, and the most common treatment was tooth extraction, reported in 71 of the 151 cases that described treatment.
If you use either medication, rinsing your mouth with water after the film fully dissolves can help reduce the risk. Take a large sip, gently swish it around your teeth and gums, and swallow. Wait at least one hour before brushing your teeth, since your mouth needs time to return to its normal state first.
How Buprenorphine Works Differently Than Other Opioids
Buprenorphine binds to opioid receptors with unusually high affinity and separates from them very slowly. This is why it works well for addiction treatment: it occupies the receptors so tightly that other opioids can’t easily displace it, which reduces the high a person would get from using other drugs. The slow release from receptors also means withdrawal symptoms, when they occur, tend to be milder and more gradual compared to withdrawal from full opioids.
This strong binding is also why buprenorphine carries a risk of precipitated withdrawal. If someone takes buprenorphine while a full opioid like fentanyl is still active in their system, the buprenorphine can push the full opioid off the receptors and trigger sudden, severe withdrawal. Research has shown the odds of severe withdrawal increase more than fivefold when buprenorphine is taken within 24 hours of fentanyl use. This risk applies to any buprenorphine formulation, whether it’s Belbuca, Suboxone, or another form.
Why the Distinction Matters
The difference between Belbuca and Suboxone isn’t just a labeling technicality. Both drugs are Schedule III controlled substances, but they exist in separate treatment ecosystems. A person taking Suboxone for opioid use disorder is on a carefully managed program that typically includes counseling and regular check-ins. A person taking Belbuca for chronic pain is following a pain management plan, often after other non-opioid options haven’t provided enough relief.
Switching between these medications, or substituting one for the other, isn’t straightforward. The massive difference in dosing alone makes a simple swap impossible without medical guidance. Someone stable on a high-dose Suboxone regimen for addiction would not get the same receptor coverage from a Belbuca dose designed for pain. And someone on Belbuca for pain would receive far more buprenorphine than needed if switched to a standard Suboxone dose.
If you’re taking one of these medications and wondering whether the other might work better for your situation, the conversation starts with your prescriber. The shared ingredient can make these drugs seem interchangeable at first glance, but their design, dosing, and intended effects are built around very different goals.